Prescribers' knowledge of and sources of information for potential drug-drug interactions: A postal survey of US prescribers

Drug Safety

Volumn 31, Issue 6, 2008, Pages 525-536

  Ko, Yu ^a   Malone, Daniel C ^b   Skrepnek, Grant H ^b   Armstrong, Edward P ^b   Murphy, John E ^b   Abarca, Jacob ^c   Rehfeld, Rick A ^b   Reel, Sally J ^d   Woosley, Raymond L ^e  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF ARIZONA   (United States)

^c WellPoint Next Rx   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF NURSING   (United States)

^e NONE

Author keywords

Adverse reaction monitoring; Drug interactions; Pharmacovigilance; Questionnaires

Indexed keywords

ALENDRONIC ACID; ALPRAZOLAM; AMANTADINE; AMFEBUTAMONE; AMOXICILLIN; ATENOLOL; CIMETIDINE; CLARITHROMYCIN; CODEINE; COTRIMOXAZOLE; CYCLOSPORIN; DIGOXIN; GLIBENCLAMIDE; IPRATROPIUM BROMIDE; ISOSORBIDE MONONITRATE; ITRACONAZOLE; METHOTREXATE; OXYBUTYNIN; PARACETAMOL; RANITIDINE; RIFAMPICIN; SILDENAFIL; SIMVASTATIN; VALACICLOVIR; VERAPAMIL; WARFARIN; ZOLPIDEM;

ARTICLE; DRUG CONTRAINDICATION; DRUG INFORMATION; DRUG SAFETY; FEMALE; HUMAN; INFORMATION RETRIEVAL; INFORMATION SERVICE; LEARNING; MALE; NORMAL HUMAN; PERSONAL DIGITAL ASSISTANT; PHARMACIST; POSTAL MAIL; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PUBLICATION; QUESTIONNAIRE; SCORING SYSTEM; UNITED STATES;

EID: 43749091716     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831060-00007     Document Type: Article

References (29)

1. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002; 287: 337-44
2. Woodwell DA, Cherry DK. National ambulatory medical care survey: 2002 summary. Adv Data 2004; 346: 1-44
3. Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 1993; 9: 51-9
4. Stanton LA, Peterson GM, Rumble RH, et al. Drug-related admissions to an Australian hospital. J Clin Pharm Ther 1994; 19: 341-7
5. Yee JL, Hasson NK, Schreiber DH. Drug-related emergency department visits in an elderly veteran population. Ann Pharmacother 2005; 39: 1990-5
6. Prince BS, Goetz CM, Rihn TL, et al. Drug-related emergency department visits and hospital admissions. Am J Hosp Pharm 1992; 49: 1696-700
7. Mason A. Fatal reaction associated with tranylcypromine and methylamphetamine [letter]. Lancet 1962; 1: 1073
8. Lloyd JT, Walker DR. Death after combined dexamphetamine and phenelzine. BMJ 1965; 2: 168-9
9. Ferslew KE, Hagadorn AN, Harlan GC, et al. A fatal drug interaction between clozapine and fluoxetine. J Forensic Sci 1998; 43: 1082-5
10. Preskorn SH, Baker B. Fatality associated with combined fluoxetine-amitriptyline therapy. JAMA 1997; 277: 1682
11. Rivers N, Homer B. Possible lethal reaction between Nardil and dextromethorphan. Can Med Assoc J 1970; 103: 85
12. Curtin PO, Jones WN. Therapeutic rationale of combining therapy with gemfibrozil and simvastatin. J Am Pharm Assoc 2007; 47 (2): 140-6
13. Flockhart DA, Drici MD, Kerbusch T, et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol 2000; 20: 317-24
14. Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351 (11): 1089-96
15. Cavuto NJ, Woosley RL, Sale M. Pharmacies and prevention of potentially fatal drug interactions. JAMA 1996; 275: 1086-7
16. Glassman PA, Belperio P, Simon B, et al. Exposure to automated drug alerts over time: effects on clinicians' knowledge and perceptions. Med Care 2006; 44: 250-6
17. Glassman PA, Simon B, Belperio P, et al. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care 2002; 40: 1161-71
18. Langdorf MI, Fox JC, Marwah RS, et al. Physician versus computer knowledge of potential drug interactions in the emergency department. Acad Emerg Med 2000; 7: 1321-9
19. Nelson Jr AA, Hutchinson RA, Mahoney D, et al. Evaluation of the utilization of medication profiles for the purpose of drug-drug interaction surveillance by pharmacists in a community setting. Drug Intell Clin Pharm 1976; 10: 274-81
20. Weideman RA, Bernstein IH, McKinney WP. Pharmacist recognition of potential drug interactions. Am J Health Syst Pharm 1999; 56: 1524-9
21. McAuley JW, Mott DA, Schommer JC, et al. Assessing the needs of pharmacists and physicians in caring for patients with epilepsy. J Am Pharm Assoc 1999; 39: 499-504
22. Ko Y, Malone DC, Abarca J, et al. Practitioners' views on computerized drug-drug interaction alerts in the VA system. J Am Med Inform Assoc 2007; 14: 56-64
23. Malone DC, Abarca J, Hansten PD, et al. Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. J Am Pharm Assoc 2004; 44: 142-51
24. Dillman DA. Mail and telephone surveys: the total design method. New York: John Wiley & Sons, Inc, 1978
25. Abarca J, Malone DC, Armstrong EP, et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc 2004; 44: 136-41
26. Chao SD, Maibach HI. Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs. Am J Clin Dermatol 2005; 6: 105-11
27. Fulda TR, Valuck RJ, Zanden JV, et al. Disagreement among drug compendia on inclusion and ratings of drug-drug interactions. Curr Ther Res 2000; 61: 540-8
28. Malone DC, Hutchins DS, Haupert H, et al. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm 2005; 62: 1983-91
29. Magnus D, Rodgers S, Avery AJ. GPs' views on computerized drug interaction alerts: questionnaire survey. J Clin Pharm Ther 2002; 27: 377-82